AQST

Aquestive Therapeutics' stock price has been significantly impacted by regulatory developments concerning Anaphylm™. On January 9, 2026, the FDA identified deficiencies in the NDA for Anaphylm™, leading to a substantial drop in AQST shares. In March 2026, Aquestive completed a Type A meeting with the FDA regarding the resubmission of the Anaphylm™ NDA and reaffirmed its guidance to resubmit the Anaphylm™ NDA in the third quarter of 2026. In April 2026, a securities fraud class-action lawsuit was filed against Aquestive Therapeutics. Despite these setbacks, the stock has seen some recovery, with a 41.13% increase over the past six months as of May 2026.